The 5 W's

A 72-Hour Update on Aurie’s De Novo Grant: FDA Creates New Device Category as Veterans Health Administration Prepares Rollout, Yet Long-Term Infection Data Still Lacking

Published: May 19, 2026
By: Zeeshan Khan
Reading time: 20 minutes
Category: Medical Devices / Healthcare Economics / Public Health

Note: May 19, 2026 – This is an update to emerging coverage of the first reusable intermittent catheter system. The FDA’s De Novo authorization creates an entirely new regulatory classification for reusable urological devices.

WASHINGTON, D.C. – May 19, 2026 – In a significant shift for medical device regulation, the U.S. Food and Drug Administration has quietly authorized the first reusable intermittent urinary catheter for market, ending a 50-year era in which single-use disposable catheters were the only option available to American patients.

The device, called the Aurie Reusable No-Touch Intermittent Catheter System™, received marketing authorization through the FDA’s Class II De Novo pathway on May 11, 2026 – creating an entirely new device classification for reusable catheters. The system pairs a 100-use no-touch catheter with a portable washer-disinfector about the size of a small water bottle.

However, while the authorization represents a potential revolution in both cost and environmental impact for the estimated 500,000 Americans who depend on intermittent catheters daily, significant questions remain unanswered: the company has not yet announced pricing for the system, long-term infection rates in real-world use are unknown, and it remains unclear how Medicare and private insurers will reimburse for a reusable device with upfront capital costs.

The authorization comes as the intermittent urinary catheters market, valued at approximately $2.49 billion in 2024, is projected to reach nearly $3.9 billion by 2032. The Veterans Health Administration has already signaled interest in deploying the Aurie system through its spinal cord injury centers, where patients often require multiple catheterizations daily for decades.

---

The Essentials: Who, What, When, Where, Why, How (Last 72 Hours)

Who: Aurie (medical device company, based in the United States); the U.S. Food and Drug Administration; approximately 500,000 Americans who use intermittent catheters regularly; the Veterans Health Administration; Medicare and Medicaid programs; private health insurers; and the broader population of taxpayers who fund federal healthcare programs.

What: The FDA authorized the first reusable intermittent urinary catheter system designed for up to 100 uses per device, paired with a portable washer-disinfector that cleans and disinfects the catheter between uses. This creates a new regulatory category – reusable intermittent catheters – that did not previously exist.

When: The FDA granted De Novo authorization on May 11, 2026. News of the authorization began appearing in medical trade publications on May 12-13, with wider coverage in MedTech and healthcare economics outlets by May 14-15. As of May 19, 2026, the device is authorized for marketing but not yet commercially available.

Where: The authorization applies across the entire United States market. The initial rollout is expected to occur through Veterans Health Administration spinal cord injury hospitals, with broader commercial availability to follow once manufacturing scales up and payer coverage decisions are finalized.

Why (Problem Addressed): Single-use catheters generate massive medical waste – approximately 14,000 tons of medical waste are produced daily in the United States – and impose significant out-of-pocket costs on patients. A typical patient who requires catheterization several times per day can spend hundreds or even thousands of dollars annually on single-use catheters, depending on insurance coverage.

How (Mechanism): The Aurie system consists of three components: a 100-use no-touch intermittent catheter designed for repeated use without the user touching the sterile insertion surface; a portable catheter washer-disinfector (about the size of a small water bottle) that uses pre-packaged supply pods to clean and disinfect the catheter between uses; and the consumable pods themselves. The FDA based its decision on extensive testing including microbiological validation (proving the washer-disinfector kills harmful bacteria) and human factors evaluations (proving patients can use the system correctly and safely).

---

Specific Changes in the Last 72 Hours

1. FDA Creates New Device Classification for Reusable Catheters

The most significant change is the creation of an entirely new regulatory category. Prior to May 11, 2026, all intermittent urinary catheters on the U.S. market were single-use disposable devices. The FDA’s De Novo pathway is reserved for novel medical devices that have no existing predicate (previously approved) equivalent.

Previous Situation (prior to May 11, 2026):

• All intermittent urinary catheters were single-use disposable devices
• No reusable catheter system had ever been authorized for the U.S. market
• Patients and healthcare systems had no regulatory pathway for reusable alternatives
• The medical device classification system had no category for reusable catheters

Current Situation (as of May 19, 2026):

• The FDA has created a new regulatory classification for reusable intermittent catheters
• The Aurie system is the first device authorized under this new category
• Other manufacturers can now use the Aurie system as a predicate device to seek authorization for their own reusable catheters through the 510(k) pathway (a faster, less burdensome process than De Novo)
• This opens the market to competition, potentially driving down prices over time

Impact Assessment: This change addresses the fundamental regulatory barrier that prevented reusable catheters from entering the U.S. market. By creating a new device classification, the FDA has established a pathway for future competitors. However, the time required for other manufacturers to develop, test, and seek authorization for competing products means Aurie will likely have market exclusivity for at least 12-24 months.

2. Veterans Health Administration Prepares for Rollout

The Veterans Health Administration has signaled interest in deploying the Aurie system through its network of spinal cord injury centers. Spinal cord injury patients are among the highest users of intermittent catheters, often requiring multiple catheterizations daily for decades.

Remaining Unknowns About VA Rollout:

Element	Status
Launch timing	Expected “later this year” (specific date not announced)
Initial VA sites	Spinal cord injury hospitals (specific locations not disclosed)
Patient eligibility criteria	Not yet published
VA reimbursement rate	Under negotiation (not disclosed)
Patient out-of-pocket costs	Unknown; depends on VA benefit tier

3. Pricing and Reimbursement Remain Unannounced

Aurie has not yet announced specific pricing for the system, including the upfront cost of the reusable catheter, the washer-disinfector, or the ongoing consumable pods. This is a critical gap in public information, as the economic case for the system depends entirely on whether the upfront costs are offset by long-term savings.

Unanswered Pricing Questions:

• What is the upfront cost of the starter system (catheter + washer-disinfector + initial pod supply)?
• What is the per-use cost of consumable pods?
• How does the per-use cost compare to single-use catheters (typically $5-15 each)?
• Will Medicare establish a new billing code for reusable catheter systems?
• Will private insurers cover the upfront capital cost, or will they reimburse only for consumables?

Expert Estimates: Based on industry analysis, a reusable catheter that replaces 100 single-use catheters could save patients and insurers 50-70 percent over the device’s lifetime, assuming the upfront cost of the washer-disinfector is amortized across multiple years of use. However, these estimates are speculative until actual pricing is announced.

4. Long-Term Infection Data Still Lacking

The FDA based its authorization on “extensive testing, including microbiological and human factors evaluations” that demonstrated “reasonable assurance of safety and effectiveness.” However, the specific data submitted to the FDA has not been made public.

Remaining Clinical Questions:

• What was the sample size and duration of the clinical studies?
• How did infection rates in reusable catheter users compare to single-use catheter users?
• What was the device failure rate over 100 use cycles?
• Were there differences in outcomes by patient population (e.g., elderly vs. younger, spinal cord injury vs. other conditions)?
• What is the real-world infection risk when patients do not follow cleaning protocols perfectly?

Regulatory Context: The De Novo pathway does not require the same level of clinical evidence as a pre-market approval (PMA) for high-risk devices. The FDA determined that the Aurie system presents “moderate risk,” justifying the less burdensome Class II classification. Critics may argue that long-term infection risk in real-world use – outside of controlled study conditions – remains insufficiently characterized.

---

Comparison: Before and After the FDA Authorization

Feature	Old Market (prior to May 11, 2026)	Current Market (as of May 19, 2026)
Reusable catheter options	NONE	Aurie system authorized
Device classification	Single-use only (no reusable category)	New Class II category created
Maximum uses per device	1 use	100 uses (per manufacturer claim)
Washing requirement	Not applicable	Washer-disinfector required
Upfront capital cost	None (per-unit pricing only)	Unknown (not yet announced)
Per-use consumable cost	Full catheter cost	Pod cost only (unknown)
VA availability	None	Expected later this year
Competitor pipeline	None	Other manufacturers can now use 510(k) pathway

---

Arguments For and Against the FDA Authorization

In Favor of the Aurie System

1. Significant Cost Reduction for Patients and Payers

The most compelling argument for the Aurie system is economic. A reusable device that replaces 100 single-use catheters could dramatically reduce recurring expenses. For uninsured or underinsured patients, this could mean the difference between adhering to prescribed catheterization schedules (which prevents serious urinary tract infections and kidney damage) and rationing supplies.

For taxpayers, the potential savings are substantial. Medicare, Medicaid, and the Veterans Health Administration collectively spend billions annually on urological supplies. If the Aurie system reduces catheter costs by even 50 percent, the cumulative savings to federal healthcare programs could reach hundreds of millions of dollars annually.

2. Environmental Sustainability

The healthcare sector is responsible for approximately 8.5 percent of U.S. carbon emissions. Reducing single-use plastic medical devices is a direct, measurable way to lower this footprint. Each single-use catheter is made of plastic, packaged in plastic, and typically discarded after one use into medical waste streams that often end up in incinerators or landfills.

The Aurie system, if widely adopted, could prevent millions of plastic catheters from entering the waste stream annually. This aligns with broader healthcare sustainability initiatives, including the Biden administration’s 2022 pledge to decarbonize the healthcare sector by 2050.

3. Supply Chain Resilience

The COVID-19 pandemic exposed vulnerabilities in medical supply chains. Single-use catheters, like many medical disposables, faced shortages when manufacturing or distribution was disrupted. A reusable system reduces dependence on just-in-time delivery of disposables, providing a buffer against future supply shocks.

4. Patient Empowerment and Independence

The system is designed for independent use. The portable washer-disinfector allows patients to clean their catheter in any setting with access to electricity and water, reducing the need to carry large quantities of supplies when traveling or working. For active patients, this could represent a meaningful improvement in quality of life.

5. Creates Path for Competition

By establishing a new regulatory category, the FDA has opened the market to future competitors. Other manufacturers can now use the Aurie system as a predicate device to seek 510(k) clearance for their own reusable catheters – a faster and less expensive regulatory pathway than the De Novo process Aurie underwent. Competition typically drives down prices and expands patient choice.

Against the Aurie System (Or Cautious Concerns)

1. Infection Risk Remains a Significant Concern

This is the most significant concern. The entire rationale for single-use catheters has been infection prevention. Urinary tract infections are among the most common healthcare-associated infections, and catheter use is a primary risk factor.

While the FDA determined that Aurie’s testing demonstrated “reasonable assurance of safety and effectiveness,” critics will reasonably ask: is “reasonable assurance” sufficient when the consequence of device failure is a potentially life-threatening kidney infection? Real-world use outside of controlled testing conditions may reveal challenges that laboratory studies did not capture.

Specific Infection Concerns:

• Patient compliance with cleaning protocols will be critical, and not all patients may follow instructions perfectly
• Biofilm formation on reusable catheters over multiple use cycles could harbor bacteria even after disinfection
• The washer-disinfector itself could become a source of contamination if not properly maintained
• Immunocompromised patients or those with recurrent UTIs may face different risk profiles than the general catheter-using population

2. Upfront Cost Barrier May Limit Access

While reusable systems save money over time, they require higher upfront investment. Aurie has not announced pricing, but the system includes the reusable catheter, the washer-disinfector (an electronic device), and ongoing consumable pods.

For patients who pay out-of-pocket or have high-deductible health plans, the initial cost may be prohibitive even if long-term savings are substantial. For insurance systems accustomed to paying per disposable unit, the reimbursement model for a reusable device with upfront capital cost is not yet established.

Unresolved Reimbursement Questions:

• Will Medicare create a new billing code for the starter system?
• Will private insurers cover the upfront capital cost as a single payment or amortize it over time?
• What happens if a patient’s insurance changes mid-year after purchasing the starter system?
• Will Medicaid programs, which operate on tight budgets, be able to absorb upfront costs even if long-term savings are higher?

3. Durability and Reliability Questions Unanswered

“100 uses” is a claim based on testing under controlled conditions. But real-world conditions vary widely. A catheter used by an elderly patient with limited dexterity may not last 100 cycles. The washer-disinfector, being an electronic device with moving parts, could fail.

Unknown Durability Factors:

• What is the actual failure rate in real-world use across diverse patient populations?
• What is the warranty period for the washer-disinfector?
• What happens if the device fails after 30 uses – does Aurie replace it at no cost?
• How easy is it to obtain replacement parts or repair service?
• Does the 100-use limit include a safety margin, or is it the maximum tested?

4. Convenience Trade-Off Is Real

There is a reason single-use catheters dominate the market: they are convenient. Use once, discard. No cleaning, no maintenance, no charging a washer-disinfector, no tracking how many uses remain.

The Aurie system requires the user to clean the catheter after each use, operate the washer-disinfector, and track remaining uses. For patients with limited hand function, cognitive impairment, visual impairment, or simply busy lives, this added complexity is a real drawback.

Convenience Barriers by Patient Population:

Patient Type	Barrier Level	Reason
Elderly with arthritis	HIGH	Difficulty operating washer-disinfector and handling small components
Spinal cord injury with limited hand function	HIGH	May require caregiver assistance, defeating independence benefit
Cognitively impaired	HIGH	May not reliably follow cleaning protocols
Visually impaired	MEDIUM-HIGH	Difficulty reading display or tracking use count
Working-age with normal function	LOW	Added steps manageable
Frequent travelers	MEDIUM	Need access to electricity and water; device adds luggage weight

5. Lack of Long-Term Real-World Data

The FDA authorization was based on pre-market testing. No long-term post-market surveillance data yet exists for the Aurie system. Important questions about infection rates, device durability, and patient adherence can only be answered after the device is in use by thousands of patients over months or years.

Post-Market Surveillance Requirements: The FDA will likely require Aurie to conduct post-market studies to track real-world outcomes. However, the specific requirements have not been made public, and the timeline for completing such studies is unknown.

---

What Has Not Changed: Single-Use Catheters Remain Available

The most important aspect of this authorization that should be emphasized is that single-use catheters remain fully available. The FDA has not banned disposable catheters, nor has it mandated the use of reusable alternatives.

Current Options for Patients (unchanged):

• Continue using single-use disposable catheters (any brand, any supplier)
• Choose the Aurie reusable system (when commercially available)
• Use a hybrid approach (reusable for daily use, single-use for travel or backup)

The authorization simply adds an option that did not exist before. Patients who prefer the convenience of single-use catheters, or who are concerned about infection risk with reusable devices, can continue using disposables without any change to their insurance coverage or out-of-pocket costs.

---

Remaining Concerns

1. Pricing and Reimbursement Still Unclear

The most immediate practical concern is the lack of pricing information. Patients and healthcare systems cannot evaluate whether the Aurie system is cost-effective for their specific situation without knowing:

• The upfront cost of the starter system
• The per-use cost of consumable pods
• Whether and how insurers will cover the system

Until these questions are answered, the economic case for the Aurie system remains theoretical rather than practical.

2. Long-Term Infection Risk Still Unknown

The FDA’s “reasonable assurance” standard for Class II devices is lower than the “valid scientific evidence” standard for Class III (high-risk) devices. While the FDA clearly believes the evidence supports safety, real-world infection rates across diverse patient populations remain unknown.

Specific Unknowns:

• What is the infection rate per 100 catheterizations with the Aurie system compared to single-use catheters?
• Are there differences by patient age, underlying condition, or immune status?
• What is the infection rate when patients do not follow cleaning protocols perfectly (the real-world scenario)?

3. Durability Claims Unverified in Real-World Use

Aurie claims the reusable catheter lasts for 100 uses. This claim is based on testing, but real-world durability may differ. A catheter that fails after 50 uses is far less cost-effective than one that lasts 100 uses. A washer-disinfector that requires repair every six months adds hidden costs.

Patients and healthcare systems have no way to verify durability claims until the device has been in widespread use for a significant period.

4. No Competitor Pipeline Yet Public

While the FDA’s creation of a new device classification theoretically opens the market to competitors, no other manufacturer has announced a reusable catheter in development for the U.S. market. Aurie will likely have market exclusivity for at least 12-24 months, during which time it can set prices without competitive pressure.

5. Patient Education and Training Requirements Unclear

The Aurie system requires patients to learn new skills: operating the washer-disinfector, tracking use counts, and following cleaning protocols. It is unclear what training and support Aurie will provide to patients, who will pay for that training, and what happens when patients make errors.

---

Media Coverage and Public Awareness

The FDA’s authorization of the first reusable catheter has received minimal mainstream media coverage as of May 19, 2026:

• Medical trade publications (MedTech Dive, DelveInsight) reported the news on May 12-13
• Healthcare economics outlets (Drug Channels, Healthcare Dive) began coverage on May 14-15
• General news outlets (CNN, NBC News, The New York Times, The Washington Post, Associated Press) have not yet published any coverage of the authorization
• Social media reaction has been minimal, confined to medical device industry forums and patient advocacy groups

This lack of coverage is striking given the potential impact on millions of patients and billions in healthcare spending. By comparison, the same week’s coverage of a celebrity legal proceeding received approximately 500 times more news mentions, according to media monitoring estimates.

The Veterans Health Administration’s planned rollout has received even less attention. No major news outlet has reported on which VA hospitals will receive the system first, how many patients will be eligible, or what the implementation timeline looks like.

---

Why This Matters to the Average Person

The FDA’s authorization of the first reusable catheter is not niche medical news. It matters to the common person for several reasons:

For patients who use catheters: This could mean hundreds or thousands of dollars in annual savings, reduced medical waste, and greater independence. A patient who spends $2,000 per year on single-use catheters could potentially reduce that cost by 50-70 percent with a reusable system.

For family members of catheter users: Caregivers who help with catheterization may find the reusable system more convenient (one device to manage) or less convenient (cleaning required). The choice between reusable and single-use will affect daily care routines.

For taxpayers: Medicare, Medicaid, and the VA spend billions on urological supplies annually. If reusable catheters reduce costs by even 20-30 percent across the federal healthcare system, the savings to taxpayers could reach hundreds of millions of dollars annually.

For anyone concerned about healthcare sustainability: The healthcare sector’s environmental footprint is massive. Reducing single-use plastic medical devices is one of the most direct ways to lower that footprint without compromising patient care. The Aurie system, if successful, could pave the way for reusable versions of other single-use medical devices (surgical instruments, respiratory supplies, etc.).

For anyone with a chronic condition: If reusable catheters prove safe and cost-effective, the regulatory pathway established by this authorization could be used for reusable versions of other medical disposables. This could transform how many chronic conditions are managed, shifting from a disposable model to a reusable one.

The bottom line: The FDA has opened the door to a fundamentally different approach to urological care – one that prioritizes reusability over disposability. Whether that door leads to cost savings and sustainability or to infection outbreaks and patient frustration depends on how well the Aurie system performs in the real world. The next 12-24 months of post-market experience will determine whether this quiet authorization becomes a landmark moment in medical device regulation or a cautionary tale.

The reusable catheter market remains a work in progress. Aurie has not yet announced pricing. The VA rollout timeline is vague. Competitors have not yet emerged. And critically, long-term real-world infection data does not yet exist. Whether the company and the FDA will adequately address these remaining concerns through transparent post-market surveillance and clear patient communication remains to be seen.

---

Current Status (As of May 19, 2026)

Element	Status
FDA De Novo authorization	GRANTED (May 11, 2026)
New device classification	CREATED (Class II, reusable intermittent catheters)
Aurie system pricing	NOT ANNOUNCED
Commercial availability	NOT YET (manufacturing scale-up in progress)
VA rollout	EXPECTED “LATER THIS YEAR” (specific date not announced)
Medicare coverage decision	PENDING (no billing code yet)
Private insurer coverage	PENDING (varies by insurer)
Competitor announcements	NONE (other manufacturers can now use 510(k) pathway)
Real-world infection data	NOT YET AVAILABLE (requires post-market surveillance)
Patient training materials	NOT YET PUBLISHED

---

Sources

• FDA De Novo authorization database (Device: Aurie Reusable No-Touch Intermittent Catheter System™) – Authorization date: May 11, 2026. Accessed via FDA.gov.
• DelveInsight (May 12-13, 2026) – “FDA Approves First Reusable Intermittent Catheter Aurie.” MedTech News coverage of authorization.
• Drug Channels (May 14-15, 2026) – Healthcare economics analysis of reusable catheter market implications.
• MedTech Dive (May 13, 2026) – “FDA clears first reusable intermittent catheter with washer-disinfector.”
• Aurie company website and announcements (May 2026) – Device specifications and VA rollout indication.
• Veterans Health Administration spinal cord injury centers – Implementation planning (as reported by Aurie, specific VA documentation not public).
• U.S. healthcare sector emissions data – Health Care Without Harm (September 2022). “Health Care Climate Footprint Report.”
• Intermittent urinary catheters market analysis – Multiple industry reports (2024-2025). Market valuation approximately $2.49 billion in 2024, projected $3.9 billion by 2032.